PL2152256T3 - Związki aktywujące telomerazę i sposoby ich zastosowania - Google Patents

Związki aktywujące telomerazę i sposoby ich zastosowania

Info

Publication number
PL2152256T3
PL2152256T3 PL08763514T PL08763514T PL2152256T3 PL 2152256 T3 PL2152256 T3 PL 2152256T3 PL 08763514 T PL08763514 T PL 08763514T PL 08763514 T PL08763514 T PL 08763514T PL 2152256 T3 PL2152256 T3 PL 2152256T3
Authority
PL
Poland
Prior art keywords
methods
activating compounds
telomerase activating
telomerase
compounds
Prior art date
Application number
PL08763514T
Other languages
English (en)
Inventor
Aviv Gazit
Shimon Slavin
Esther Priel
Sara Yitzchak
Original Assignee
Ben Gurion Univ Of The Negev Research And Development Authority
Shimon Slavin
Aviv Gazit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion Univ Of The Negev Research And Development Authority, Shimon Slavin, Aviv Gazit filed Critical Ben Gurion Univ Of The Negev Research And Development Authority
Publication of PL2152256T3 publication Critical patent/PL2152256T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5022—Aromatic phosphines (P-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
PL08763514T 2007-06-04 2008-06-04 Związki aktywujące telomerazę i sposoby ich zastosowania PL2152256T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92487507P 2007-06-04 2007-06-04
US92952507P 2007-07-02 2007-07-02
US92952407P 2007-07-02 2007-07-02
US692408P 2008-02-06 2008-02-06
EP08763514.0A EP2152256B1 (en) 2007-06-04 2008-06-04 Telomerase activating compounds and methods of use thereof
PCT/IL2008/000756 WO2008149353A2 (en) 2007-06-04 2008-06-04 Telomerase activating compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2152256T3 true PL2152256T3 (pl) 2015-03-31

Family

ID=40094272

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08763505T PL2152663T3 (pl) 2007-06-04 2008-06-03 Związki triarylowe oraz kompozycje zawierające te związki
PL08763514T PL2152256T3 (pl) 2007-06-04 2008-06-04 Związki aktywujące telomerazę i sposoby ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08763505T PL2152663T3 (pl) 2007-06-04 2008-06-03 Związki triarylowe oraz kompozycje zawierające te związki

Country Status (19)

Country Link
US (7) US8604245B2 (pl)
EP (3) EP2152663B1 (pl)
JP (6) JP5508258B2 (pl)
KR (4) KR101560844B1 (pl)
CN (4) CN101742906A (pl)
AU (2) AU2008259342B2 (pl)
CA (4) CA2690004C (pl)
CY (1) CY1115919T1 (pl)
DK (2) DK2152663T3 (pl)
EA (4) EA201401193A1 (pl)
ES (2) ES2465216T3 (pl)
HR (2) HRP20140394T1 (pl)
IL (4) IL202425A (pl)
MX (2) MX2009013354A (pl)
PL (2) PL2152663T3 (pl)
PT (2) PT2152663E (pl)
SI (2) SI2152663T1 (pl)
TW (1) TWI430796B (pl)
WO (3) WO2008149345A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2152663T3 (pl) 2007-06-04 2014-09-30 Ben Gurion Univ Of The Negev Research And Development Authority Związki triarylowe oraz kompozycje zawierające te związki
KR101682259B1 (ko) * 2008-12-22 2016-12-05 포라 가세이 고교 가부시키가이샤 멜라닌 생산 억제제
CA2795981C (en) 2009-05-18 2017-06-27 Geron Corporation Compositions and methods for increasing telomerase activity
CR20160207A (es) * 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN110505872A (zh) * 2017-02-12 2019-11-26 本古里安大学内盖夫研究和发展局 用于生育力和相关应用的端粒酶活性化合物
IL257470B2 (en) * 2018-02-11 2023-12-01 Ben Gurion Univ Of The Negev Research And Development Authority Telomerase activator compounds for use in fertility and related applications
KR102099335B1 (ko) 2017-11-03 2020-04-09 한국과학기술연구원 Prox1의 발현 또는 활성 조절제를 포함하는 텔로머라제 역전사효소의 발현 조절용 조성물 또는 텔로머라제 역전사효소 조절제의 스크리닝 방법
US10098922B1 (en) * 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
CN112513297B (zh) 2018-03-28 2024-10-22 得克萨斯州大学系统董事会 鉴定从外排体分离的dna中的表观遗传改变
WO2020040161A1 (ja) * 2018-08-24 2020-02-27 三菱瓦斯化学株式会社 化合物、及びそれを含む組成物、並びに、レジストパターンの形成方法及び絶縁膜の形成方法
KR20210049094A (ko) * 2018-08-24 2021-05-04 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 화합물, 및 그것을 포함하는 조성물, 그리고, 레지스트패턴의 형성방법 및 절연막의 형성방법
WO2020141525A1 (en) * 2018-12-31 2020-07-09 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Capture flow assay device and methods
EP3920889B1 (en) * 2019-02-08 2024-11-13 Board of Regents, The University of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
KR102214612B1 (ko) 2020-03-23 2021-02-15 한국과학기술연구원 Prox1의 발현 또는 활성 조절제를 포함하는 텔로머라제 역전사효소의 발현 조절용 조성물 또는 텔로머라제 역전사효소 조절제의 스크리닝 방법
US12305233B1 (en) 2020-07-09 2025-05-20 Arizona Board Of Regents On Behalf Of Arizona Ultra-high-throughput assay for telomerase repeat addition processivity
KR102666469B1 (ko) 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
KR102666470B1 (ko) 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
CN116850119B (zh) * 2023-07-19 2024-10-22 上海联衡生物科技有限公司 端粒酶组合物的制备方法及在防脱发护发素中的应用
KR102647264B1 (ko) 2023-11-01 2024-03-14 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093557A (en) * 1976-09-16 1978-06-06 Hercules Incorporated Process for inhibiting corrosion of metals in aqueous systems
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4740330A (en) * 1986-09-03 1988-04-26 The Dow Chemical Company Method for allylating aromatic hydroxyl-containing compounds
US4783495A (en) * 1987-11-20 1988-11-08 Ciba-Geigy Corporation (Hydroxyphenyl) silane stabilizers
US4835202A (en) * 1987-11-20 1989-05-30 Ciba-Geigy Corporation (Hydroxyphenyl) phosphine stabilized compositions
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
JPH02121941A (ja) * 1988-10-28 1990-05-09 Teijin Chem Ltd ハロゲン化トリスフェニル誘導体および難燃性熱可塑性樹脂組成物
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5219727A (en) * 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04268328A (ja) * 1991-02-22 1992-09-24 Idemitsu Petrochem Co Ltd 分岐ポリカーボネート
JPH04328555A (ja) * 1991-04-26 1992-11-17 Fuji Photo Film Co Ltd ポジ型フオトレジスト組成物
US5198531A (en) * 1991-06-14 1993-03-30 Research Diagnostic Antibodies Polymeric resin for peptide synthesis
JP3560243B2 (ja) * 1992-02-03 2004-09-02 ヘキスト・セラニーズ・コーポレーション 紫外線安定剤，酸化防止剤および着色剤である４´−ヒドロキシアセトフェノン，４−ヒドロキシスチレン，１，１，１−トリス（４´−ヒドロキシフェニル）エタン，および１，３，５−トリス（４´−ヒドロキシフェニル）ベンゼンの誘導体
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP3534787B2 (ja) * 1993-05-06 2004-06-07 本州化学工業株式会社 トリスフェノールへのヒドロキシベンジル基付加体
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
JP3026707B2 (ja) * 1993-10-05 2000-03-27 出光石油化学株式会社 分岐状ポリカーボネートの製造方法
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
EP0783303B1 (en) * 1994-09-16 2002-11-27 President And Fellows Of Harvard College Use of aromatic halides for treating mammalian cell proliferation
US6028103A (en) * 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
DE4439947A1 (de) 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5571825A (en) * 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE69734983T2 (de) 1996-03-20 2006-09-07 President And Fellows Of Harvard College, Cambridge Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
JP4128247B2 (ja) 1996-11-01 2008-07-30 株式会社リコー フェノール系化合物及び電子写真感光体
JPH10153884A (ja) * 1996-11-25 1998-06-09 Minolta Co Ltd 静電潜像現像用トナー
JP2001512307A (ja) 1997-02-05 2001-08-21 １１４９３３６ オンタリオ インコーポレーテッド プロエキセンジンをコードするポリヌクレオチドならびにその作製方法および使用
DE19711617A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
AU4730699A (en) 1998-07-02 2000-01-24 Millipore Corporation Process for coating a solid surface with a liquid composition
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
DE19844547C2 (de) 1998-09-29 2002-11-07 Aventis Pharma Gmbh Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6380378B1 (en) * 1998-12-24 2002-04-30 Toagosei Company, Ltd. Nucleotide compound, nucleotide block oligonucleotide, and method for producing them
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6417208B1 (en) 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
JP4195145B2 (ja) * 1999-04-01 2008-12-10 出光興産株式会社 ポリカーボネートの製造方法
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001008677A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
IL148291A0 (en) 1999-09-16 2002-09-12 Tanabe Seiyaku Co Aromatic nitrogen-containing 6-membered cyclic compounds
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU7961800A (en) * 1999-10-28 2001-05-08 Kyowa Hakko Kogyo Co. Ltd. Thiazolidinedione derivatives
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CZ301401B6 (cs) 1999-12-22 2010-02-17 Metabasis Therapeutics, Inc. Bisamidátfosfonátová predléciva a farmaceutické prostredky s jejich obsahem
US6803375B1 (en) * 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
JP4187934B2 (ja) 2000-02-18 2008-11-26 富士フイルム株式会社 ポジ型レジスト組成物
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002013798A2 (en) 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
ATE512964T1 (de) * 2000-10-12 2011-07-15 Cancer Rec Tech Ltd N8,n13-disubstituierte chinoä4,3,2,klüacridinium salze als arzneimittel
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1351671A1 (en) * 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
MXPA03006936A (es) 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
IL158873A0 (en) 2001-06-07 2004-05-12 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
CN1990468A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7045523B2 (en) * 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
HUP0401998A2 (hu) 2001-11-02 2005-01-28 Pfizer Products Inc., PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20070042962A1 (en) * 2002-02-04 2007-02-22 Adams David S Peptide dependent upregulation of telomerase expression
JP2005527524A (ja) 2002-03-14 2005-09-15 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｐｄｅ１１ａ阻害剤を用いる糖尿病の処置方法
JP2006520777A (ja) 2003-03-17 2006-09-14 ファイザー・プロダクツ・インク Ｐｄｅ５阻害剤を用いる１型糖尿病の治療
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP4517723B2 (ja) 2003-05-22 2010-08-04 住友ベークライト株式会社 ナフトキノンジアジドスルホン酸エステル、それを用いたポジ型感光性樹脂組成物、半導体装置及び表示素子
MXPA05013844A (es) * 2003-06-23 2006-07-06 Geron Corp Composiciones y metodos para incrementar la actividad de telomerasa.
WO2005003129A1 (en) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｐｄｅ１０ａ阻害剤を用いる糖尿病および関連障害の処置方法
US20050049208A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
JP2007532116A (ja) * 2004-04-07 2007-11-15 キアジェン ノース アメリカン ホールディングス，インコーポレイティド １成分型および２成分型のＤＮＡＰｏｌＩＩＩレプリカーゼとその使用
JP2008501776A (ja) 2004-06-07 2008-01-24 ファイザー・プロダクツ・インク 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ１０の阻害
WO2006007864A1 (en) * 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
JP4929569B2 (ja) * 2004-08-20 2012-05-09 東レ株式会社 高分子電解質材、ならびにそれを用いた高分子電解質膜、膜電極複合体および高分子電解質型燃料電池
US7541392B2 (en) * 2004-09-14 2009-06-02 E.I. Du Pont De Nemours And Company Materials leading to improved dental composites and dental composites made therefrom
CA2596355C (en) * 2005-01-31 2015-01-06 Ception Therapeutics, Inc. Tumor necrosis factor inhibitors
AU2006210641A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
JP5211438B2 (ja) 2005-06-09 2013-06-12 東レ株式会社 樹脂組成物およびそれを用いた表示装置
NZ575904A (en) * 2006-09-28 2011-11-25 Univ Otago Triphenylphosphonium thionitrite nitric oxide donors
PL2152663T3 (pl) 2007-06-04 2014-09-30 Ben Gurion Univ Of The Negev Research And Development Authority Związki triarylowe oraz kompozycje zawierające te związki

Also Published As

Publication number Publication date
US8609736B2 (en) 2013-12-17
EA200971141A1 (ru) 2010-10-29
HRP20140394T1 (hr) 2014-08-01
WO2008149345A3 (en) 2010-02-25
CY1115919T1 (el) 2017-01-25
JP5922328B2 (ja) 2016-05-24
JP5508258B2 (ja) 2014-05-28
CA2690013A1 (en) 2008-12-11
CN101742994A (zh) 2010-06-16
EP2152663A4 (en) 2011-11-09
JP2016145199A (ja) 2016-08-12
US20170305837A1 (en) 2017-10-26
EA200971140A1 (ru) 2010-10-29
CA2963857A1 (en) 2008-12-11
US8604245B2 (en) 2013-12-10
TW200916101A (en) 2009-04-16
KR20100039828A (ko) 2010-04-16
WO2008149353A2 (en) 2008-12-11
ES2465216T3 (es) 2014-06-05
ES2527759T3 (es) 2015-01-29
EP2152256A2 (en) 2010-02-17
PT2152663E (pt) 2014-06-03
EP2152256A4 (en) 2011-11-02
IL202425A0 (en) 2010-06-30
PT2152256E (pt) 2015-02-04
SI2152663T1 (sl) 2014-08-29
US20100267667A1 (en) 2010-10-21
CA2690004A1 (en) 2008-12-11
IL249838A0 (en) 2017-02-28
EP2826472A3 (en) 2015-05-20
CA2913459A1 (en) 2008-12-11
EA201500403A1 (ru) 2016-01-29
SI2152256T1 (sl) 2015-04-30
JP5964898B2 (ja) 2016-08-03
WO2008149353A3 (en) 2010-02-25
MX2009013353A (es) 2010-07-06
IL202425A (en) 2015-09-24
US20140142068A1 (en) 2014-05-22
KR20170029015A (ko) 2017-03-14
EP2152663A2 (en) 2010-02-17
CN103553939A (zh) 2014-02-05
US9670139B2 (en) 2017-06-06
CA2690004C (en) 2018-01-23
CA2690013C (en) 2016-02-09
KR20100039830A (ko) 2010-04-16
HRP20141264T1 (hr) 2015-05-08
KR20160051682A (ko) 2016-05-11
JP2010529107A (ja) 2010-08-26
US9663448B2 (en) 2017-05-30
WO2008149345A2 (en) 2008-12-11
EP2826472A2 (en) 2015-01-21
CN101742994B (zh) 2014-06-11
AU2008259350A1 (en) 2008-12-11
EP2152663B1 (en) 2014-03-19
US20140107336A1 (en) 2014-04-17
US9670138B2 (en) 2017-06-06
EP2152256B1 (en) 2014-10-15
DK2152663T3 (da) 2014-06-23
CN104000806A (zh) 2014-08-27
US20170305836A1 (en) 2017-10-26
CN104000806B (zh) 2017-09-15
JP6134824B2 (ja) 2017-05-24
TWI430796B (zh) 2014-03-21
IL202424A0 (en) 2010-06-30
JP2010529961A (ja) 2010-09-02
MX2009013354A (es) 2010-07-06
JP2017019774A (ja) 2017-01-26
DK2152256T3 (en) 2015-01-19
CN101742906A (zh) 2010-06-16
JP2015007068A (ja) 2015-01-15
EA021544B1 (ru) 2015-07-30
EA201401193A1 (ru) 2015-08-31
KR101560844B1 (ko) 2015-10-15
US20100256382A1 (en) 2010-10-07
CN103553939B (zh) 2018-02-02
WO2008149346A3 (en) 2010-02-25
AU2008259350B2 (en) 2013-06-06
KR101600374B1 (ko) 2016-03-07
IL240895A0 (en) 2015-10-29
EA022472B1 (ru) 2016-01-29
US20140142067A1 (en) 2014-05-22
WO2008149346A2 (en) 2008-12-11
AU2008259342B2 (en) 2014-07-10
PL2152663T3 (pl) 2014-09-30
IL202424A (en) 2017-01-31
JP2017149762A (ja) 2017-08-31
US10214481B2 (en) 2019-02-26
AU2008259342A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
PL2152256T3 (pl) Związki aktywujące telomerazę i sposoby ich zastosowania
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
ZA201104467B (en) Heterocyclic compounds and methods of use
EP2094085A4 (en) ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE
IL213547A0 (en) Compounds and methods of use
EP2340244A4 (en) COMPOUNDS AND APPLICATION PROCEDURES
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
EP2191458A4 (en) FINGER-FITTED DEVICES AND METHODS OF USE THEREOF
IL222947A0 (en) Luminaire and methods of use
ZA201001051B (en) Benzylbenzene derivatives and methods of use
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0906980A2 (pt) Composição de derivados e maleatados
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
ATE511509T1 (de) Azaindolylverbindungen und anwendungsverfahren
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
EP2079544A4 (en) ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE
IL206125A0 (en) Azaindolizines and methods of use
BRPI0922344A2 (pt) inibidores de tfpi e métodos de uso
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL202740A0 (en) Quinazolinone compounds and methods of use thereof
IL213695A0 (en) Adhesive compounds and methods of use thereof